Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | — | -$1.94M | -$48.4M | — | $73.0M | -$12.8M |
| Net income | — | $8.20M | -$52.6M | — | $42.0M | -$39.2M |
| EPS (diluted) | — | — | -$0.38 | — | $72.93 | -$3.95 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | — | -$1.49M | -$35.6M | — | -$20.3M | -$17.3M |
| Capital expenditures | — | — | $306K | — | — | $4.00K |
| Free cash flow | — | — | -$35.9M | — | — | -$17.3M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | — | $497K | $9.75M | $31.2M | $13.0K | $3.01M |
| Total assets | $81.0K | $277M | $10.8M | $6.84M | $3.14M | $5.56M |
| Total liabilities | $59.6K | $17.9M | $143M | $160M | $31.7M | $60.6M |
| Shareholders' equity | $21.4K | -$224M | -$270M | -$153M | -$28.6M | -$55.0M |
| Retained earnings | -$3.59K | -$17.0M | -$475M | -$474M | -$432M | -$471M |
| Shares (wtd avg diluted) | — | — | 139M | 516K | 576K | 9.92M |
Every figure is extracted from AEON Biopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.